Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab (GSK3511294) in severe uncontrolled eosinophilic asthma
CTR20212150Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of depemokimab in asthma, sponsored by GSK. Started Sep 2021; status: completed.
02
Drugs
depemokimab
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20212150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212150.